Method Article

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells

DOI:

10.3791/61879

⸱

March 14th, 2021

 ,  ,  , 
1Stanford Cardiovascular Institute, Stanford University School of Medicine, 2Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, 3Department of Radiology, Stanford University School of Medicine

In This Article

Summary

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Here, we describe an easy-to-use methodology to generate 3D self-assembled cardiac microtissue arrays composed of pre-differentiated human-induced pluripotent stem cell-derived cardiomyocytes, cardiac fibroblasts, and endothelial cells. This user-friendly and low cell requiring technique to generate cardiac microtissues can be implemented for disease modeling and early stages of drug development.

Abstract

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Generation of human cardiomyocytes (CMs), cardiac fibroblasts (CFs), and endothelial cells (ECs) from induced pluripotent stem cells (iPSCs) has provided a unique opportunity to study the complex interplay among different cardiovascular cell types that drives tissue development and disease. In the area of cardiac tissue models, several sophisticated three-dimensional (3D) approaches use induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to mimic physiological relevance and native tissue environment with a combination of extracellular matrices and crosslinkers. However, these systems are complex to fabricate without microfabrication expertise and require several weeks to self-assemble. Most importantly, many of these systems lack vascular cells and cardiac fibroblasts that make up over 60% of the nonmyocytes in the human heart. Here we describe the derivation of all three cardiac cell types from iPSCs to fabricate cardiac microtissues. This facile replica molding technique allows cardiac microtissue culture in standard multi-well cell culture plates for several weeks. The platform allows user-defined control over microtissue sizes based on initial seeding density and requires less than 3 days for self-assembly to achieve observable cardiac microtissue contractions. Furthermore, the cardiac microtissues can be easily digested while maintaining high cell viability for single-cell interrogation with the use of flow cytometry and single-cell RNA sequencing (scRNA-seq). We envision that this in vitro model of cardiac microtissues will help accelerate validation studies in drug discovery and disease modeling.

Introduction

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Drug discovery and disease modeling in the field of cardiovascular research face several challenges due to a lack of clinically relevant samples and inadequate translational tools1. Highly complex pre-clinical models or oversimplified in vitro single-cell models do not exhibit pathophysiological conditions in a reproducible manner. Therefore, several miniaturized tissue-engineered platforms have evolved to help bridge the gap, with the goal of achieving a balance between ease of application in a high-throughput manner and faithful recapitulation of tissue function2,3. With the advent of induced pluripotent stem cell (iPSC) technology, tissue engineering tools can be applied to patient-specific cells with or without underlying cardiovascular disease state to answer research questions4,5,6. Such tissue engineered models with cellular composition similar to the heart tissue could be utilized in drug development efforts to test for cardiotoxicity and dysfunction induced by pathological changes in behavior of one or multiple cell types.

Self-assembled microtissues or organoids derived from human iPSCs are three-dimensional (3D) structures that are miniature tissue-like assemblies exhibiting functional similarities to their in vivo counterparts. There are several different approaches that allow formation of organoids in situ via directed differentiation of iPSCs or through the formation of embryoid bodies4. The resulting organoids are an indispensable tool to study morphogenetic processes that drive organogenesis. However, the presence of a variety of cell populations and differences in self-organization can lead to variability in outcomes between different organoids5. Alternatively, pre-differentiated cells that are self-assembled into microtissues with tissue-specific cell types to study local cell-cell interactions are excellent models, where it is feasible to isolate the self-assembled components. Particularly in human cardiac research, development of 3D cardiac microtissues with multicellular components has proven to be challenging when cells are derived from different patient lines or commercial sources.

To improve our mechanistic understanding of cell behaviors in a physiologically relevant, personalized, in vitro model, ideally all component cell types should be derived from the same patient line. In the context of a human heart, a truly representative cardiac in vitro model would capture the crosstalk among predominant cell types, namely, cardiomyocytes (CMs), endothelial cells (ECs), and cardiac fibroblasts (CFs)6,7. The faithful recapitulation of a myocardium not only requires biophysical stretch and electrophysiological stimulation, but also cell-cell signaling that arise from supporting cell types such as ECs and CFs8. CFs are involved in the synthesis of extracellular matrix and maintaining tissue structure; and in a pathological state, CFs can induce fibrosis and alter electrical conduction in the CMs9. Similarly, ECs can regulate contractile properties of CMs through paracrine signaling and supplying vital metabolic demands10. Hence, there is a need for human cardiac microtissues composed of all three major cell types to allow physiologically relevant high-throughput experiments to be conducted.

Here, we describe a bottom-up approach in fabrication of cardiac microtissues by derivation of human iPSC-derived cardiomyocytes (iPSC-CMs), iPSC-derived endothelial cells (iPSC-ECs), and iPSC-derived cardiac fibroblasts (iPSC-CFs) and their 3D culture in uniform cardiac microtissue arrays. This facile method of generating spontaneously beating cardiac microtissues can be utilized for disease modeling and rapid testing of drugs for functional and mechanistic understanding of heart physiology. Furthermore, such multicellular cardiac microtissue platforms could be exploited with genome editing techniques to emulate cardiac disease progression over time under chronic or acute culture conditions.

Access restricted. Please log in or start a trial to view this content.

Protocol

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

1. Medium, reagent, culture plate preparation

  1. Cell wash solution for cell culture: Use 1x phosphate buffered saline (PBS) or Hanks balanced salt solution (HBSS) without calcium or magnesium.
  2. Cardiomyocyte differentiation media
    1. Prepare differentiation Medium #1 by adding 10 mL supplement (50x B27 plus insulin) to 500 mL cardiomyocyte basal medium (RPMI 1640).
    2. Prepare differentiation Medium #2 by adding 10 mL supplement (50x B27 minus insulin) to 500 mL cardiomyocyte basal medium (RPMI 1640).
    3. Prepare purification Medium #3 by adding supplement (50x B27 plus insulin) to 500 mL cardiomyocyte basal medium (RPMI 1640) minus glucose.
  3. Endothelial growth media and Magnetic-activated cell sorting (MACS) reagents
    1. Prepare endothelial growth medium (EGM) with commercially available endothelial cell growth medium supplement kit.
    2. Prepare cell separation sorting buffer solution by diluting bovine serum albumin (BSA) stock solution to 1:20 with rinsing solution.
  4. Cardiac fibroblast differentiation medium: Prepare cardiac fibroblast differentiation medium with fibroblast basal medium (DMEM-high glucose) and Serum-Free Fibroblast Life Factors kit.
  5. Cardiac microtissue fabrication and maintenance medium: Prepare filtered medium with cardiomyocyte basal medium (RPMI 1640) with supplement (50x B27 plus insulin) and EGM in 70/30 v/v% ratio.
  6. Small molecule and growth factor stock solutions
    1. For differentiation of all three cell types, prepare 200 µL aliquots of GSK3-beta inhibitor CHIR 99021 (6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile); Wnt inhibitor IWR-1-endo (4-(1,3,3a,4,7,7a-Hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-N-8-quinolinyl-Benzamide; and transforming growth factor beta (TGF-β) inhibitor SB431542 (4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamid) at 10 mM concentration in dimethyl sulfoxide (DMSO).
    2. For human iPSC-EC differentiation, prepare 100 µL aliquots of basic fibroblast growth factor (bFGF) (20 µg/mL), vascular endothelial growth factor 165 (VEGF165; 50 µg/mL), and bone morphogenetic protein 4 (BMP4; 20 µg/mL) in 0.1% (w/v) BSA in ultrapure distilled water. Store the aliquots at -20 °C; for long-term storage, aliquots can be stored at -80 °C for up to 1 year.
  7. Pre-coating plates for maintenance of iPSC-CMs, iPSC-ECs, and iPSC-CFs.
    1. Prepare basement membrane matrix medium coated 6-well plates for iPSC-CM re-plating by diluting Growth Factor Reduced (GFR) basement membrane matrix medium in DMEM/F12 in a 1:200 ratio. Add 2 mL of diluted basement membrane matrix medium to each well of the 6-well plate and leave it to set for at least 2 to 4 h.
    2. Pre-coat 6-well plate or 10 cm dish with gelatin. Liquefy 2% gelatin solution in a water bath at 37 °C and prepare filtered 0.2% (v/v) gelatin in PBS in an appropriate volume as needed. Coat the culture plate with 10 mL of 0.2% gelatin for at least 30 min at 37 °C prior to use.
      ​NOTE: Gelatin plates can be used for both iPSC-CFs and iPSC-ECs after MACS.
  8. Fabrication of microtissue molds: Prepare 2% low melting agarose solution in PBS in a dry 100 mL glass bottle. Sterilize the agarose at 121 °C, 15 psi for 20 min prior to use. Autoclave the casting silicone micro-molds at 121 °C, 15 psi for 15 min.
  9. Solutions for digestion, immunostaining, and flow cytometry
    1. For microtissue digestion, prepare an enzyme digestion buffer of Dispase I (1 U/mL) and Liberase (3 U/mL) in PBS. Keep this solution on ice.
    2. For both cell and microtissue fixation, use ice cold commercially available fixation reagent containing 4.2% paraformaldehyde (PFA).
    3. Prepare 0.25% Triton X-100 in PBS for permeabilization and 0.1% Tween-20 for washes. The solution can be stored at room temperature.
    4. For fluorescence-activated cell sorting (FACS) analyses, prepare FACS buffer [PBS or HBSS with 2% fetal bovine serum (FBS)] and store at 4 °C.
    5. For immunostaining, prepare 2% normal goat/donkey/rabbit serum in PBS. Choose the serum species based on the host in which the antibodies were raised.

2. Cardiac differentiation and purification

NOTE: All iPSCs should be maintained at ~75% to 80% confluency prior to cardiomyocyte differentiation. iPSCs used for this protocol were derived from peripheral blood mononuclear cells (PBMCs) using Sendai virus reprogramming performed at the Stanford Cardiovascular Institute (SCVI) Biobank.

  1. Prior to differentiation, culture iPSC colonies up to passage (P20).
  2. Remove the iPSC culture medium from the 6-well plate and wash the cells once with 2 mL PBS.
  3. On day 0, begin mesendoderm induction by adding 2 mL of differentiation Medium #1 with CHIR (6 µM final) in each well. The final concentration may vary between 6 to 9 µM for different iPSC lines. Hence, it is recommended to test different CHIR concentrations on a 6-well plate to identify optimal cardiac mesoderm induction.
  4. On day 2, recover the cells by replacing with fresh 2 mL Medium #1 in each well.
  5. On day 3, replace medium in each well with 2 mL differentiation Medium #1 with Wnt inhibitor IWR-1-endo (5 µM) to induce cardiac-lineage specification.
  6. On day 5, recover the cells by replacing medium with fresh 2 mL Medium #1 in each well.
  7. On day 7, replace medium with 2 mL Medium #2 in each well. Spontaneous beating of cardiomyocytes may be observed as early as day 8-9. For some lines, beating cells may appear as late as day 11.
  8. For purification of the differentiation culture, replace with 2 mL minus glucose Medium #3 in each well on day 10.
  9. On day 13, recover the cells by changing the medium with 2 mL plus glucose Medium #2 in each well.
  10. On day 16, perform second round of purification with 2 mL of Medium #3 in each well.
  11. Recover the cells on day 19 with 2 mL plus glucose Medium #2.
  12. On day 20, wash the wells once with 1 mL PBS and dissociate the cells using 1 mL 10x Trypsin for 6 min at 37 °C. After incubation, the cells are lifted off the well surface into single cells for less than 15 s and added to 15 mL conical tube with equal volume of Medium #2 to neutralize the enzyme. Centrifuge the cell suspension for 3 min at 270 x g.
  13. Resuspend the cell pellet in 3 mL Medium #3. Count the cells and add appropriate volume of Medium #3 to plate a total of ~3 million cells in each well of a new basement membrane matrix medium coated 6-well plate. On the second day after re-plating, replace the medium with fresh 2 mL Medium #2, and replenish with 2 mL Medium #2 every other day until trypsinization of cardiomyocytes for freezing or future experiments.

3. Endothelial cell differentiation and MACS

  1. At 75% to 80% iPSC confluency, wash the plate with PBS, 2 mL per well.
  2. Begin differentiation at day 0 by replacing with 2 mL of differentiation Medium #1 with 6 µM CHIR.
  3. On day 2, replace the medium with 2 mL of differentiation Medium #1 with 2 µM CHIR.
  4. On day 4, replace the medium with 2 mL of EGM supplemented with 20 ng bFGF-2, 50 ng VEGF165, and 20 ng BMP4.
  5. Change the medium with 2 mL of EGM supplemented with growth factors every 2 days from day 6 to day 10. Addition of TGFβ inhibitor (SB431542) at 8 µM concentration is optional to promote endothelial expansion and suppress differentiation of other mesenchymal origin cell types.
  6. On day 12, begin steps for MACS by rinsing each well with 1 mL of PBS followed by cell dissociation using 1 mL of 10x Trypsin in each well of a 6-well plate for 8 min at 37 °C.
  7. Prepare an equal volume of EGM medium in a 50 mL conical tube to neutralize the dissociation enzyme. Place a 40 µm cell strainer on the 50 mL conical tube and pass the dissociated cell suspension through the strainer. Change the filter for every 2 to 3 dissociated wells.
  8. Enumerate the total viable cells using 0.4% Trypan blue using a hemocytometer or an automated cell counter.
  9. Pellet the cell suspension at 300 x g for 5 min in a pre-cooled centrifuge set at 4 °C.
  10. Discard the supernatant and resuspend the cell pellet in appropriate volume of sorting buffer based on the total count in step 3.8.
    NOTE: Add 80 µL of sorting buffer per 107 total cells.
  11. For magnetic bead labeling, add 20 µL of FcR Blocking reagent per 107 cells and incubate for 5 min.
  12. Add 20 µL of CD144 or CD31 Microbeads per 107 cells and mix well. Incubate the cell suspension in dark at 4 °C for 15 min.
  13. Add 20 mL of sorting buffer to wash the labeled cells and pellet the cells 300 x g for 5 min in a pre-cooled centrifuge set at 4 °C.
  14. Resuspend the cell pellet in 3 mL of sorting buffer and leave it on ice.
  15. Prepare a magnetic separation column by placing the column in the separator notch.
  16. Equilibrate the column by rinsing with 3 mL of sorting buffer and collect the flow through in a waste conical tube.
  17. Once the rinsing buffer flows through, resuspend the cell suspension thoroughly to break any clumps and apply the cell suspension onto the column.
  18. After the cell suspension has flowed through, wash the column with 3 mL of sorting buffer three times to remove any unlabeled cells.
  19. Remove the column from the separator and place it in a 15 mL conical tube for CD144+/CD31+ cell elution.
  20. Add 5 mL of sorting buffer onto the column and immediately flush the magnetically labeled cells with the plunger.
  21. Determine the viable cell number using 0.4% Trypan blue using a hemocytometer or an automated cell counter.
  22. Centrifuge the cell suspension in a pre-cooled centrifuge at 300 x g for 3 min.
  23. Resuspend the cell pellet in appropriate volume of EGM with 5-8 µM of TGFβ inhibitor (SB431542) based on the total count in step 3.21.
  24. Plate this passage 0 (P0) cells at an appropriate cell density (4 x 104 cells/cm2) on a pre-coated 0.2% gelatin plate.
  25. For P0 and P1, continue to replenish the medium with fresh EGM every 2 days with TGFβ inhibitor. From P2, cells can be cultured in endothelial growth medium without TGFβ inhibitor.

4. Cardiac fibroblast differentiation

  1. Allow iPSCs to become 90% to 95% confluent; wash each well with 1 mL PBS.
  2. Begin differentiation at day 0 by adding 2 mL of differentiation Medium #1 with 11 µM CHIR. For sensitive iPSC lines, the concentration may vary between 9-10 µM.
  3. On day 1, observe the plate. It is normal to observe significant cell death with ~30% to 40% cells adhered to the plate.
  4. On day 3, add 2 mL of differentiation Medium #1 with 5 µM IWR-1-endo to promote expansion of cardiac progenitors.
  5. On day 4, replace the medium with 2 mL of cardiac fibroblast differentiation medium. Replace with fresh medium every 2 days till day 16.
  6. On day 18, detach the cells using 1 mL of 10x Trypsin in each well of a 6-well plate for 10 min at 37 °C.
  7. Disrupt the cell layer thoroughly and pass the cell suspension through a 70 µm cell strainer in a 50 mL conical tube containing equal volume of DMEM/F12 medium supplemented with 5% FBS.
  8. Determine the viable cell number using 0.4% Trypan blue using a hemocytometer or an automated cell counter.
  9. Centrifuge the cell suspension at 300 x g for 5 min to obtain a pellet.
  10. For the first re-plating, resuspend the cell pellet in an appropriate volume of differentiation medium and plate at a cell density (6 x 104 cells/cm2) on a 0.2% gelatin coated plate until 90% confluency.
  11. Split the plate and maintain the cardiac fibroblasts in regular DMEM/F12 with 10% serum on gelatin coated plates.

5. Casting of cardiac microtissue molds and cell seeding

  1. Melt the agarose in a microwave in a 100 mL glass bottle until boiling. Spray the agarose bottle and place it in the biosafety cabinet. Allow the agarose to cool down for ~3 min.
  2. Pipette 700 µL of molten agarose in a silicone micro-mold of 9 x 9 array. Avoid generating bubbles while pipetting.
  3. Carefully place the mold on a pre-cooled ice block to accelerate agarose gelation.
  4. Ensure that once the agarose is gelled, it becomes translucent. Carefully bend around the edges of the micro-mold to loosen the agarose replica. Then, gently peel the replica from all sides to detach the agarose replica from the silicone micro-mold.
  5. Transfer the agarose microtissue tray containing 81 circular recesses (800 µm diameter; 800 µm depth) into a sterile 12-well plate.
  6. Add 2 mL of PBS to the agarose microtissue tray and inspect under the microscope for any trapped bubbles or irregular shaped wells.
  7. Submerge the agarose tray in 2 mL 70% ethanol overnight, followed by UV treatment in the biosafety cabinet for 1 h.
  8. Prior to use, remove the 70% ethanol and wash twice with distilled water and a final wash with 2 mL PBS.
  9. Trypsinize, neutralize, and count iPSC-CMs, iPSC-ECs, and iPSC-CFs and place the cell suspensions on ice.
  10. Remove the PBS from the well and the cell seeding chamber carefully without touching the recesses.
  11. In a new tube, mix iPSC-CMs, iPSC-ECs, and iPSC-CFs in 7:2:1 ratio, respectively, to achieve a final cell density of 106 cells/mL. Higher cell densities will result in larger microtissues.
    NOTE: Do not exceed 2 x 106 cells/mL.
  12. Carefully add the 200 µL of the cell suspension dropwise in the seeding chamber.
  13. Allow the cells to settle at 37 °C in a CO2 incubator for 2 h.
  14. Add microtissue fabrication medium surrounding the agarose mold to just cover the surface of the inner chamber.
  15. After 24 h, the cells self-assemble and compact significantly in the circular recesses. Replace with fresh medium every 2 days for maintenance.

6. Fixation and permeabilization of cells and cardiac microtissues for immunostaining

  1. For each individual cell types, culture the cells separately on basement membrane matrix medium or gelatin coated chamber slides (approximately 2.5-3 x 105 cells/mL). Cardiac microtissues can be collected in 15 mL conical tube by gently flushing them out of the circular recesses.
  2. Aspirate the medium and rinse the cells or microtissues with 1 mL PBS; thereafter, fix with the fixation buffer containing 4.2% PFA for 20 min for the chamber slides and 1 h for microtissues at room temperature.
  3. Aspirate the PFA and add 1 mL of permeabilizing solution (0.25% Triton X-100 in PBS) for 5 to 7 min for chamber slides and 20 min for microtissues in 15 mL conical tube.
    NOTE: From this step onwards, the samples can be gently rocked on a benchtop rocking platform.
  4. Aspirate the permeabilizing solution and rinse once with 2 to 3 mL of PBS.
  5. Incubate the cells with 500-1,000 µL of blocking solution (2% to 5% normal goat serum or donkey serum) for at least 1 h for the chamber slides and 3 to 4 h for the microtissues.
  6. Incubate the cells or cardiac microtissues with conjugated antibodies prepared in the blocking solution sufficient to cover the sample. Incubate with anti-cardiac Troponin-T (cTnT2) (1:50), anti-CD31 (1:75), and anti-DDR2/Vimentin (1:50) for 1 h for the chamber slides and overnight at 4 °C for cardiac microtissues.
  7. Wash the chamber slides three times with 500 µL 0.1% Tween-20 for 5 min between each wash and a final wash with PBS.
  8. For the cardiac microtissues, wash with 2 mL 0.1% Tween-20 five times with 20 min duration between each wash. Perform a final wash step for an additional 20 min.
  9. Incubate the cells or microtissues with 4',6-diamidino-2-phenylindole (DAPI) (1 µg/mL) prior to confocal microscopy.
  10. For cardiac microtissues, transfer carefully to a 35 mm glass bottom dish and add PBS to submerge microtissues.
  11. For 3D imaging, using a 20x or 40x oil immersion objective gain center focus of the microtissue and adjust exposure parameters for each fluorophore.
  12. For obtaining a Z-stack, set first and last coordinates in Live mode with a total imaging depth of 100-200 µm with 5-10 µm slice interval.

7. Digestion of cardiac microtissues and preparation of cells for flow cytometry

  1. To digest microtissues, gently flush the microtissues with Medium #1 out of the circular recesses using a wide-bore 1 mL pipette tip into a 15 mL conical tube.
  2. Allow the microtissues to settle and aspirate the medium carefully and rinse the cells or microtissues with 1 mL PBS and add 200-300 µL of enzyme digestion buffer for 20 min at 37 °C. At 10 min, mix the microtissues gently for 1 min and incubate again at 37 °C for the remainder of time.
  3. After incubation, use a regular 1 mL pipette tip to mix the microtissues vigorously to obtain a turbid cell suspension.
  4. Once the microtissues are sufficiently digested into single cells, immediately neutralize the cell suspension with 5 mL of medium containing 5% FBS and strain the cell suspension through a 40 µm cell strainer. Count the total number of cells and centrifuge the single cell suspension at 300 x g for 5 min at 4 °C.
  5. Aspirate the supernatant and resuspend 1 x 105-1 x 106 cells in 100 µL annexin-binding buffer with FITC Annexin V and 100 µg/mL propidium iodide (PI) or To-Pro3 dead cell exclusion dye for 10 min on ice.
  6. After incubation, add 300 µL of the annexin binding buffer to the cell suspension and transfer to a round bottom FACS tube for flow cytometry analysis. Use the correct lasers and emission filters for the select fluorophores.
  7. For quantification of cell surface markers using fixed cells, perform the fixation and permeabilization of the cell pellet as described in steps 6.2 and 6.3.
  8. After permeabilization, rinse the cell pellet and incubate the cells with respective conjugated antibodies for 1 h. Wash the cell pellet in 4 mL FACS buffer (2% FBS in PBS) and centrifuge at 300 x g for 3 min. Repeat the wash step twice.
  9. Resuspend the cells in 200-300 µL FACS buffer for flow cytometry analysis.
  10. Adjust the forward and side scatter properties with an unstained sample and consider using an isotype control for each fluorophore to adjust the laser voltages. Collect a minimum of 20,000 events for data analysis.

8. Performing contraction analyses of spontaneously beating cardiac microtissues

  1. Record videos of cardiac microtissues to capture at least three beats. Set the recording resolution to at least 1280 x 720 pixels at frame rate >30 frames per second and save the video in .AVI format.
  2. Run the MotionGUI script11 in a MATLAB environment to launch the user interface.
  3. Find the .AVI file location in your folder to load the video. Then, enter the frame rate at which the video was captured in the Input panel.
  4. In the advanced input panel, a pixel size may be specified based on the resolution and the capture magnification.
  5. A suitable macroblock pixel size can be specified (default 16) and a detectable pixel motion depending on the strength of microtissue contraction.
  6. After adjusting the parameters, click on Get Motion Vectors to begin the analysis.
  7. Select a region of interest with the Choose AOI radio button to exclude areas surrounding the single microtissue in the circular recess.
  8. Use the function Map Time Ave to generate a mean contraction heatmap based on motion detected on X and Y axes.
  9. For peak tracing data, use the function Get Contraction Data to automatically measure the contraction and relaxation peaks.
  10. In the event of a low signal-to-noise ratio, apply a peak height and distance threshold to correctly annotate the maximum contraction velocity (blue dot) and maximum relaxation velocity (red triangle).
  11. After setting the correct thresholds, select Analyze Peaks to obtain the contraction and relaxation values with beat rate and beat interval.
  12. Obtain measurements from a minimum of 25 individual microtissues for statistical analyses.

Access restricted. Please log in or start a trial to view this content.

Results

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Immunostaining and flow cytometry characterization of iPSC-derived CMs, ECs, and CFs
To generate cardiac microtissues composed of iPSC-CMs, iPSC-ECs, and iPSC-CFs, all three cell types are differentiated and characterized individually. In vitro differentiation of iPSCs to iPSC-CMs has improved over the past several years. However, the yield and purity of iPSC-CMs differ from line to line. The current protocol yields over 75% pure iPSC-CMs that spontaneously start beating around day 9 (

Access restricted. Please log in or start a trial to view this content.

Discussion

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

To generate cardiac microtissues from pre-differentiated iPSC-CMs, iPSC-ECs, and iPSC-CFs, it is essential to obtain a highly pure culture for better control of cell numbers after contact-inhibited cell compaction within the cardiac microtissues. Recently, Giacomelli et. al.18 have demonstrated the fabrication of cardiac microtissues using iPSC-CMs, iPSC-ECs, and iPSC-CFs. Cardiac microtissues generated using the described method consist of ~5,000 cells (70% iPSC-CMs, 15% iPSC-ECs, and 15% iPSC-CF...

Access restricted. Please log in or start a trial to view this content.

Disclosures

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

J.C.W. is a cofounder of Khloris Biosciences but has no competing interests, as the work presented here is completely independent. The other authors report no conflicts.

Acknowledgements

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

We thank Dr. Amanda Chase for her helpful feedback on the manuscript. Funding support was provided by the Tobacco-Related Disease Research Program (TRDRP) of the University of California, T29FT0380 (D.T.) and 27IR-0012 (J.C.W.); American Heart Association 20POST35210896 (H.K.) and 17MERIT33610009 (J.C.W.); and National Institutes of Health (NIH) R01 HL126527, R01 HL123968, R01 HL150693, R01 HL141851, and NIH UH3 TR002588 (J.C.W).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
12-well platesFisher Scientific08-772-29
3D micro-moldsMicrotissues12-81 format
6-well platesFisher Scientific08-772-1B
AutoMACS Rinsing SolutionThermo Fisher ScientificNC9104697
B27 Supplement minus InsulinLife TechnologiesA1895601
B27 Supplement plus InsulinLife Technologies17504-044
BD CytofixBD Biosciences554655
BD Matrigel, hESC-qualified matrixBD Biosciences354277
Cardiac Troponin T AntibodyMiltenyi130-120-403
CD144 (VE-Cadherin) MicroBeadsMiltenyi130-097-857
CD31 AntibodyMiltenyi130-110-670
CD31 MicrobeadsMiltenyi130-091-935
CHIR-99021SelleckchemS2924
DDR2Santa Cruz Biotechnologysc-81707
Dead Cell Apoptosis Kit with Annexin V FITC and PIThermo Fisher ScientificV13242
Dispase IMillipore Sigma4942086001
DMEM, high glucose (4.5g/L) no glutamine medium11960044
DMEM/F-12 basal mediumGibco11320033
Dulbecco's phosphate buffered saline (DPBS), no calcium, no magnesiumLife Technologies14190-136
EGM2 BulletKitLonzaCC-3124
Fetal bovine serumLife Technologies10437
FibroLife Serum-Free Fibroblast LifeFactors KitLifeLIne Cell TechnologyLS-1010
Glucose free RPMI mediumLife Technologies11879-020
Goat serumLife Technologies16210-064
Human FGF-basicThermo Fisher Scientific13256029
Human VEGF-165PeproTech100-20
IWR-1-endoSelleckchemS7086
Liberase TLMillipore Sigma5401020001
LS Sorting ColumnsMiltenyi130-042-401
MACS BSA Stock solutionMiltenyi130-091-376
MACS Rinsing BufferMiltenyi130-091-222
MidiMACS SeparatorMiltenyi130-042-302
RPMI mediumLife Technologies11835055
SB431542SelleckchemS1067
TO-PRO 3Thermo Fisher ScientificR37170
Triton X-100Millipore SigmaX100-100ML
TrypLE Select 10XThermo Fisher Scientificred
Vimentin Alexa Fluor® 488-conjugated AntibodyR&D SystemsIC2105G

References

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Neofytou, E., O'Brien, C. G., Couture, L. A., Wu, J. C. Hurdles to clinical translation of human induced pluripotent stem cells. Journal of Clinical Investigation. 125 (7), 2551-2557 (2015).
  2. Lancaster, M. A., Knoblich, J. A. Organogenesis in a dish: Modeling development and disease using organoid technologies. Science. 345 (6194), 1247125(2014).
  3. Liu, C., Oikonomopoulos, A., Sayed, N., Wu, J. C. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. Development. 145 (5), 156166(2018).
  4. Yin, X., Mead, B. E., Safaee, H., Langer, R., Karp, J. M., Levy, O. Engineering stem cell organoids. Cell Stem Cell. 18 (1), 25-38 (2016).
  5. Giacomelli, E., et al. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development. 144 (6), 1008-1017 (2017).
  6. Kurokawa, Y. K., George, S. C. Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening. Advances in Drug Delivery Reviews. 96, 225-233 (2016).
  7. Cartledge, J. E., et al. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovascular Research. 105 (3), 260-270 (2015).
  8. Ravenscroft, S. M., Pointon, A., Williams, A. W., Cross, M. J., Sidaway, J. E. Cardiac non-myocyte cells show enhanced pharmacological function suggestive of contractile maturity in stem cell derived cardiomyocyte microtissues. Toxicology Science. 152 (1), 99-112 (2016).
  9. Ieda, M., et al. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Developmental Cell. 16 (2), 233-244 (2009).
  10. Brutsaert, D. L. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiological Reviews. 83 (1), 59-115 (2003).
  11. Huebsch, N., et al. Automated video-based analysis of contractility and calcium flux in human-induced pluripotent stem cell-derived cardiomyocytes cultured over different spatial scales. Tissue Engineering Part C Methods. 21 (5), 467-479 (2015).
  12. Burridge, P. W., et al. Chemically defined generation of human cardiomyocytes. Nature Methods. 11 (8), 855-860 (2014).
  13. Gu, M., et al. Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism. European Heart Journal. 36 (13), 806-816 (2015).
  14. Williams, I. M., Wu, J. C. Generation of endothelial cells from human pluripotent stem cells. Arteriosclerosis, Thrombosis and Vascular Biology. 39 (7), 1317-1329 (2019).
  15. Zhang, H., Shen, M., Wu, J. C. Generation of quiescent cardiac fibroblasts derived from human induced pluripotent stem cells. Methods in Molecular Biology. , Springer. New York. 1-7 (2020).
  16. Zhang, H., et al. Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis. Circulation Research. 125 (5), 552-566 (2019).
  17. Zhang, J., et al. Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors. Nature Communications. 10 (1), 2238-2315 (2019).
  18. Giacomelli, E., et al. Human-iPSC-derived cardiac stromal cells enhance maturation in 3d cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. Cell Stem Cell. 26 (6), 862-879 (2020).
  19. Burridge, P. W., Holmström, A., Wu, J. C. Chemically defined culture and cardiomyocyte differentiation of human pluripotent stem cells. Current Protocols in Human Genetics. 87 (1), 1-15 (2015).
  20. Lian, X., et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nature Protocols. 8 (1), 162-175 (2013).
  21. Buikema, J. W., et al. Wnt activation and reduced cell-cell contact synergistically induce massive expansion of functional human iPSC-derived cardiomyocytes. Cell Stem Cell. 27 (1), 50-63 (2020).
  22. Feyen, D. A. M., et al. Metabolic maturation media improve physiological function of human iPSC-derived cardiomyocytes. Cell Reports. 32 (3), 107925(2020).
  23. Karbassi, E., et al. Cardiomyocyte maturation: Advances in knowledge and implications for regenerative medicine. Nature Reviews Cardiology. 17 (6), 341-359 (2020).
  24. Li, Z., Hu, S., Ghosh, Z., Han, Z., Wu, J. C. Functional characterization and expression profiling of human induced pluripotent stem cell- and embryonic stem cell-derived endothelial cells. Stem Cells Development. 20 (10), 1701-1710 (2011).
  25. Lian, X., et al. Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. Stem Cell Report. 3 (5), 804-816 (2014).
  26. Gu, M. Efficient differentiation of human pluripotent stem cells to endothelial cells. Current Protocols in Human Genetics. 98 (1), 64(2018).
  27. Acharya, A., et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development. 139 (12), 2139-2149 (2012).
  28. Wessels, A., et al. Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. Development Biology. 366 (2), 111-124 (2012).
  29. Ali, S. R., et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circulation Research. 115 (7), 625-635 (2014).
  30. McMurtrey, R. J. Analytic and numerical models of oxygen and nutrient diffusion, metabolism dynamics, and architecture optimization in three-dimensional tissue constructs with applications and insights in cerebral organoids. Tissue Engineering Part C Methods. (3), 221-249 (2015).
  31. Thomas, D., O'Brien, T., Pandit, A. Toward customized extracellular niche engineering: progress in cell-entrapment technologies. Advanced Materials. 30 (1), 1703948(2018).
  32. Thomas, D., Shenoy, S., Sayed, N. Building Multi-dimensional induced pluripotent stem cells-based model platforms to assess cardiotoxicity in cancer therapies. Front Pharmacol. 12, 39(2021).
  33. Rhee, J. -W., et al. Modeling secondary iron overload cardiomyopathy with human induced pluripotent stem cell-derived cardiomyocytes. Cell Reports. 32 (2), 107886(2020).
  34. Paik, D. T., Cho, S., Tian, L., Chang, H. Y., Wu, J. C. Single-cell RNA sequencing in cardiovascular development, disease, and medicine. Nature Reviews Cardiology. 17 (8), 457-473 (2020).
  35. Nguyen, Q. H., Pervolarakis, N., Nee, K., Kessenbrock, K. Experimental considerations for single-cell RNA sequencing approaches. Frontiers in Cell and Developmental Biology. 6, 108(2018).
  36. Lau, E., Paik, D. T., Wu, J. C. Systems-wide approaches in induced pluripotent stem cell models. Annual Reviews in Pathology. 14 (1), 395-419 (2019).
  37. Maddah, M., et al. A non-invasive platform for functional characterization of stem-cell-derived cardiomyocytes with applications in cardiotoxicity testing. Stem Cell Report. 4 (4), 621-631 (2015).
  38. Sala, L., et al. Musclemotion: A versatile open software tool to quantify cardiomyocyte and cardiac muscle contraction in vitro and in vivo. Circulation Research. 122 (3), 5-16 (2018).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Cardiac MicrotissuesStromal Vascular FractionFlow CytometrySingle Cell RNA SequencingConfocal MicroscopyAgarose Mold TechniqueCell Seeding DensityContractile Function AnalysisImmunofluorescence Staining

Related Articles